Hutchmed (China) Limited

Net Asset Value • Oct 30, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9698D

Hutchison China Meditech Limited

30 October 2015

Total Voting Rights

London: Friday, 30 October 2015: For information purposes, Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) hereby notifies the market that as at 30 October 2015, the issued share capital of Chi-Med consisted of 56,533,118 ordinary shares of US$1.00 each, with each share carrying one right to vote and with no shares held in treasury.

The above figure of 56,533,118 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, Chi-Med under the Financial Conduct Authority's Disclosure Rules and Transparency Rules.

Ends

Enquiries

Chi-Med   Christian Hogg, CEO	Telephone:      +852 2121 8200
Panmure Gordon (UK) Limited    Richard Gray    Andrew Potts	Telephone:      +44 20 7886 2500
Citigate Dewe Rogerson   Anthony Carlisle    David Dible	Telephone:      +44 20 7638 9571 Mobile:             +44 7973 611 888 Mobile:             +44 7967 566 919

About Chi-Med

Chi-Med is a China-based, globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products.  Its Innovation Platform focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market.  Its Commercial Platform manufactures, markets and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001).  For more information, please visit: www.chi-med.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

TVREAKEEDDXSFEF